| abstract |
A method for inhibiting or reducing the activity or expression of deregulated FLT3 tyrosine kinase in a subject suffering from a proliferative disease. A method of administering a therapeutically or prophylactically effective amount of a compound of the following formula (crenoranib) or a pharmaceutically acceptable salt or solvate thereof: The compound is administered orally, intravenously, or intraperitoneally in a therapeutically or prophylactically effective amount of 50-500 mg per day in at least one of the following ways: continuous, intermittent, systemic, or topical. [Selection figure] None |